Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AddLife Says Growth, Margins and Cash Flow Are All Improving — Is the MedTech Roll-Up Back on Track?

In its second-quarter 2026 report, published in July, the company struck a markedly more confident tone. Chief executive Fredrik Dalborg said AddLife's companies were performing well across the board, with stronger margins, good growth and increased cash flow. Investors agreed: the shares jumped roughly …

Ankur Sharma | 13 August 2026

ADICET's Off-the-Shelf CAR-T Bet Moves Toward a Pivotal Path — Could Autoimmune Disease Be the Breakthrough?

The headline question is whether that pivot can carry Adicet from encouraging Phase 1 signals to a genuine registrational programme. As of 12 August 2026 the company has reported positive preliminary lupus data, held FDA interactions on a pivotal design, and guided to a …

Ankur Sharma | 13 August 2026

Diaceutics Shares Slide Despite Reporting 75% ARR Growth

The AIM-listed precision medicine data group posted a striking jump in annualRecurring Revenueand swung back to profit, yet Diaceutics shares have fallen sharply in recent weeks as investors weigh valuation against execution risk.

Divya Sood | 13 August 2026

SkinBioTherapeutics Shares Slide as Governance Fallout and Cash Burn Keep Investors on Edge

Months after a fabricated-revenue scandal forced a restatement of its accounts, SkinBioTherapeutics shares are still under pressure, with a shrinking cash pile now adding to the list of investor concerns.

Divya Sood | 13 August 2026

ProBiotix Health Shares Whipsaw as 53% H1 Revenue Surge and EBITDA Swing Fail to Calm a Volatile Micro-Cap Register

ProBiotix Health reported a swing to EBITDA and net profit alongside 53%Revenuegrowth in its first-half results, yet the thinly traded AQSE stock has remained highly volatile, underscoring howIlliquidsmall-cap shares can move sharply on modest volumes even when the underlying numbers improve.

Divya Sood | 13 August 2026

Aclaris Has Multiple 2026 Biotech Catalysts — Could Its Next Clinical Readout Change Everything?

On 6 August 2026 the company reported second-quarter results and laid out a dense schedule of catalysts. Chief executive Dr Neal Walker described the first half as "a period of strong execution" that positions Aclaris "for an exciting second half of the year with …

Ankur Sharma | 13 August 2026

ABIONYX Secures Up to €33 Million and Targets Sepsis — Could CER-001 Become a Company-Making Catalyst?

For a clinical-stage biotech, cash is oxygen — and in mid-2026 ABIONYX Pharma (EPA:ABNX) secured a fresh supply. In late May 2026 the French company launched a fully securedCapitalincrease alongside structuredDebtfor an aggregate of up to approximately €33m, completed by late June. Management says …

Ankur Sharma | 13 August 2026

Abivax Crashes More Than 30% on Safety Fears — Could October's Data Rewrite the Entire Story?

The headline asks whether October's data could rewrite the story. The honest answer, as of 12 August 2026, is that the story had already partly rewritten itself: in late June, additional data and an expanded safety database prompted a powerful rebound. This article examines …

Ankur Sharma | 13 August 2026

Acadia Has a Major Alzheimer's Psychosis Readout Looming — Could One Phase 2 Result Reset the Stock?

The stakes are high because Acadia has been here before: pimavanserin failed to win clearance in dementia and Alzheimer's psychosis earlier this decade, and now a new molecule carries the same ambition. On the evidence available to 12 August 2026, the headline's framing is …

Ankur Sharma | 13 August 2026

Abingdon Health Revenue Jumps 45% — Is This Tiny Diagnostics Stock Approaching a Profitability Inflection?

The headline poses a fair question: is Abingdon approaching a profitability inflection? The evidence is encouraging but nuanced. Adjusted EBITDA profit in one half-year is not the same as sustained bottom-line profit, and the group still carries losses, thin margins and negative operating cash …

Ankur Sharma | 13 August 2026
Support

Hi! How can we help you today?

Loading…